Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease

被引:1
|
作者
He, Qiongyao [1 ]
He, Wu [2 ,5 ]
Dong, Hui [3 ]
Guo, Yujin [1 ]
Yuan, Gang [4 ]
Shi, Xiaoli [4 ]
Wang, Dingkun [3 ]
Lu, Fuer [3 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Integrated Tradit Chinese & Western Med, Tongji Med Coll, Wuhan 430030, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol, Wuhan 430030, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan 430030, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol,Dept Internal Med, Wuhan 430030, Peoples R China
[5] Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China
基金
中国国家自然科学基金;
关键词
Capillarization; Liver sinusoidal endothelial cells; Endothelial dysfunction; Angiogenesis; Steatosis; PLACEBO-CONTROLLED TRIAL; LOW-DENSITY-LIPOPROTEIN; HEPATIC STELLATE CELLS; PPAR-ALPHA ACTIVATION; CD8(+) T-CELLS; GROWTH-FACTOR; NONALCOHOLIC STEATOHEPATITIS; HEPATOCELLULAR-CARCINOMA; PORTAL-HYPERTENSION; PHYSICAL-ACTIVITY;
D O I
10.1186/s12964-024-01720-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Liver sinusoidal endothelial cells (LSECs) are highly specialized endothelial cells that represent the interface between blood cells on one side and hepatocytes on the other side. LSECs not only form a barrier within the hepatic sinus, but also play important physiological functions such as regulating hepatic vascular pressure, anti-inflammatory and anti-fibrotic. Pathologically, pathogenic factors can induce LSECs capillarization, that is, loss of fenestra and dysfunction, which are conducive to early steatosis, lay the foundation for the progression of metabolic dysfunction-associated fatty liver disease (MAFLD), and accelerate metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. The unique localization, phenotype, and function of LSECs make them potential candidates for reducing liver injury, inflammation, and preventing or reversing fibrosis in the future.
引用
收藏
页数:18
相关论文
共 50 条
  • [2] The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Martin-Mateos, Rosa
    Albillos, Agustin
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [4] LIVER FIBROSIS IN ASIANS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Kim, Byung Ik
    Sohn, Won
    Kwon, Heon-Ju
    Cho, Yong Kyun
    [J]. HEPATOLOGY, 2021, 74 : 1022A - 1022A
  • [5] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
  • [6] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [7] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    [J]. Diabetology & Metabolic Syndrome, 14
  • [8] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    [J]. LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [9] Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Bhopale, Kamlesh K.
    Srinivasan, Mukund P.
    [J]. LIVERS, 2023, 3 (04): : 597 - 617
  • [10] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260